Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Innoviva stock price, quote, forecast and news

INVA
US45781M1018
A2AC9U

Price

19.07
Today +/-
-0.31
Today %
-1.77 %
P

Innoviva stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Innoviva stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Innoviva stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Innoviva stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Innoviva's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Innoviva Stock Price History

DateInnoviva Price
9/6/202419.07 undefined
9/5/202419.41 undefined
9/4/202419.69 undefined
9/3/202419.52 undefined
8/30/202419.38 undefined
8/29/202419.10 undefined
8/28/202419.17 undefined
8/27/202419.11 undefined
8/26/202418.94 undefined
8/23/202418.86 undefined
8/22/202418.64 undefined
8/21/202418.55 undefined
8/20/202418.49 undefined
8/19/202418.53 undefined
8/16/202418.36 undefined
8/15/202418.41 undefined
8/14/202418.36 undefined
8/13/202418.55 undefined
8/12/202418.25 undefined
8/9/202418.28 undefined

Innoviva Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Innoviva, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innoviva from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innoviva’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Innoviva. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Innoviva’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Innoviva’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innoviva’s growth potential.

Innoviva Revenue, EBIT and net profit per share

DateInnoviva RevenueInnoviva EBITInnoviva Net Income
2029e563.65 M undefined0 undefined147.4 M undefined
2028e459.82 M undefined205.22 M undefined117.41 M undefined
2027e377.6 M undefined162.18 M undefined85.51 M undefined
2026e376.25 M undefined128.32 M undefined83.27 M undefined
2025e347.35 M undefined115.28 M undefined72.74 M undefined
2024e345.38 M undefined103.23 M undefined33.82 M undefined
2023310.46 M undefined113.89 M undefined179.72 M undefined
2022331.3 M undefined207 M undefined213.9 M undefined
2021391.9 M undefined375.1 M undefined265.9 M undefined
2020336.8 M undefined321.1 M undefined224.4 M undefined
2019261 M undefined246.4 M undefined157.3 M undefined
2018261 M undefined238.3 M undefined395.1 M undefined
2017217.2 M undefined183.6 M undefined134.1 M undefined
2016133.6 M undefined109 M undefined59.5 M undefined
201553.9 M undefined31.6 M undefined-18.8 M undefined
20148.4 M undefined-33.9 M undefined-168.5 M undefined
20134.5 M undefined-28.8 M undefined-170.7 M undefined
2012135.8 M undefined-13 M undefined-18.5 M undefined
201124.5 M undefined-109.7 M undefined-115.3 M undefined
201024.2 M undefined-78.3 M undefined-83.9 M undefined
200924.4 M undefined-80.3 M undefined-85.3 M undefined
200823.1 M undefined-87.8 M undefined-93.6 M undefined
200722 M undefined-168.6 M undefined-160 M undefined
200619.6 M undefined-179.2 M undefined-166 M undefined
200512.1 M undefined-149.6 M undefined-143.2 M undefined
20048.9 M undefined-106.4 M undefined-102.7 M undefined

Innoviva Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000038121922232424241354853133217261261336391331310345347376377459563
-----166.6750.0058.3315.794.554.35--462.50-97.04100.00562.50150.9463.1620.28-28.7416.37-15.35-6.3411.290.588.360.2721.7522.66
-----------------------95.7786.13------
00000000000000000000000317267000000
-47-103-74-83-72-106-149-179-168-87-80-78-109-13-28-33311091832382463213752071131031151281622050
-----2,400.00-1,325.00-1,241.67-942.11-763.64-378.26-333.33-325.00-454.17-9.63-700.00-412.5058.4981.9584.3391.1994.2595.5495.9162.5436.4529.8633.1434.0442.9744.66-
-41-94-64-79-70-102-143-166-160-93-85-83-115-18-170-168-185913439515722426521317933728385117147
-129.27-31.9123.44-11.3945.7140.2016.08-3.61-41.88-8.60-2.3538.55-84.35844.44-1.18-89.29-427.78127.12194.78-60.2542.6818.30-19.62-15.96-81.56118.1815.282.4137.6525.64
45.145.145.145.145.133.353.35960.561.46372.182.190.9102.4112.1115.4123.2119.9113.4113.4113.694.395.286.88000000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Innoviva Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Innoviva is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                           
148.689.2257.1161.9201.1126.8200.6155.4309.6240.9248.5465.1240.5187.3150.4129.1114.9350.8246.5201.5291193.51
1.50.42.110.60.30.30.30.20.21.13.410.626.246.870.583.379.493.9110.764.184.08
00001.20.20.30.10.50.10.100000000000
00000000007.510.40000000055.940.74
1.81.75.23.94.46.78.86.263.544.31.10.80.80.80.811.61.432.525.89
151.991.3264.4166.8207.3134210162316.3244.7261.2483.2252.2214.3198200.4199431.2342313.6443.5344.22
20.315.813.213.215.120.116.212.910.210.49.210.20.30.20.40.20.20003.43.02
00038.134.52.5000095.255.442.900000438.3483.8403560.98
10.610.43.12.51.81.51.20.90.40.20.100000000000
00000000000124.3208.2194.4180.5166.7152.9139.1125.3111.4350.5314.12
0000000000000000000026.717.91
1085.34.33.93.88.85.54.23.438.218.1000196.1154.59417.44.33.27
40.934.221.658.155.327.926.219.314.814107.5198.1269.5194.6180.9166.9349.2293.6657.6612.6787.9899.29
0.190.130.290.220.260.160.240.180.330.260.370.680.520.410.380.370.550.7210.931.231.24
                                           
367.5367.50.50.50.60.60.60.60.80.911.11.21.11.111110.70.70.63
0.070.070.670.680.840.870.90.931.181.231.491.81.451.351.281.261.261.261.261.261.161.09
-295.4-366-468.6-611.8-777.8-937.8-1,031.5-1,116.8-1,200.6-1,316-1,334.5-1,505.2-1,673.7-1,692.4-1,632.9-1,498.7-1,103.7-946.4-722-456.1-204.9-25.19
-2,600-1,500-10,800-5,5000100500000100200-100000000000
0000000000000000000000
0.140.070.190.060.06-0.07-0.14-0.19-0.02-0.090.160.3-0.22-0.34-0.35-0.240.150.310.540.810.961.07
1.63.25.98.11673.31.82.15.85.447.600.80.10.6000.102.96.72
8.18.214.421.824.22616.813.215.820.92027.511.611.811.39.15.75.465.833.630.14
1.65.711.217.119.422.623.923.922.118.84.69.32.10.90.9000002.21.28
25000000000000000000000
2.83.12.41.200000000007.825000096.20
39.120.233.948.259.655.64438.94045.53084.413.713.520.134.75.75.46.15.8134.938.13
7.94.41.80.60.50.4172.8172.8172.6172.5172.5287.5725.6733.1708.3574.4382.9377.1385.5394.7444.2446.23
000000000000000000005.80.56
10.333.159.9116.4139172.3154.3158.7141127.811.110.25.653.60.90.60.20.1080.883.62
18.237.561.7117139.5172.7327.1331.5313.6300.3183.6297.7731.2738.1711.9575.3383.5377.3385.6394.7530.8530.42
57.357.795.6165.2199.1228.3371.1370.4353.6345.8213.6382.1744.9751.6732610389.2382.7391.7400.5665.7568.55
0.190.130.290.220.260.160.240.180.330.260.370.680.520.410.380.370.540.70.931.211.631.64
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Innoviva provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Innoviva's financial health and stability.

Assets

Innoviva's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Innoviva must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Innoviva after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Innoviva's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-64-79-70-102-143-166-160-93-85-83-115-18-170-168-1859134406191293368220179
455444475673312131414131313131935
00000000000000000-196416076254
192937743428-311-16-5-1405-9-16-22-28-163-14-166-24
1164126222336403849515762381731199-38-76-62-48
000000025555892548401711991111
00000000000000000000000
-47-58-31-47-58-104-104-99-58-75-88-127-129-1301061141223257313363201141
-1-70-2-3-5-9-100-3-2-87-135000000000
3651-13-1003-18110-671-40-55-58-219-65159-4-233-18-31443-56-66
3758-12-986-12120-662-39-52-55-13170159-4-233-18-31443-56-66
00000000000000000000000
-126-28-3-2-1016600002814340-18-63-230-130087-96
0400217614776112312523615348-19-78-99-100-393-29-75
-266-27213314671731123125235397149-106-97-163-238-23-29-452-55-171
-------------36.00-277.00----6.00-10.00-30.00-59.00-113.00-
0000000000000-57-87-10000000
-1359-7365-5122145-44115-1185048-4662-41-44-11215-31-4589-97
-49.2-65.6-32.5-49.9-62-110.5-114.2-100.9-58.8-76-91.9-130.1-217.3-266.410.160.7141.7223.5257.5313.1363.8201.6140.65
00000000000000000000000

Innoviva stock margins

The Innoviva margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innoviva. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innoviva.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Innoviva's sales revenue. A higher gross margin percentage indicates that the Innoviva retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Innoviva's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Innoviva's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innoviva's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innoviva. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innoviva's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Innoviva Margin History

Innoviva Gross marginInnoviva Profit marginInnoviva EBIT marginInnoviva Profit margin
2029e86.27 %0 %26.15 %
2028e86.27 %44.63 %25.53 %
2027e86.27 %42.95 %22.64 %
2026e86.27 %34.1 %22.13 %
2025e86.27 %33.19 %20.94 %
2024e86.27 %29.89 %9.79 %
202386.27 %36.68 %57.89 %
202295.83 %62.48 %64.56 %
202186.27 %95.71 %67.85 %
202086.27 %95.34 %66.63 %
201986.27 %94.41 %60.27 %
201886.27 %91.3 %151.38 %
201786.27 %84.53 %61.74 %
201686.27 %81.59 %44.54 %
201586.27 %58.63 %-34.88 %
201486.27 %-403.57 %-2,005.95 %
201386.27 %-640 %-3,793.33 %
201286.27 %-9.57 %-13.62 %
201186.27 %-447.76 %-470.61 %
201086.27 %-323.55 %-346.69 %
200986.27 %-329.1 %-349.59 %
200886.27 %-380.09 %-405.19 %
200786.27 %-766.36 %-727.27 %
200686.27 %-914.29 %-846.94 %
200586.27 %-1,236.36 %-1,183.47 %
200486.27 %-1,195.51 %-1,153.93 %

Innoviva Stock Sales Revenue, EBIT, Earnings per Share

The Innoviva earnings per share therefore indicates how much revenue Innoviva has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Innoviva earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Innoviva's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Innoviva’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Innoviva's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Innoviva Revenue, EBIT and net profit per share

DateInnoviva Sales per ShareInnoviva EBIT per shareInnoviva Earnings per Share
2029e9.01 undefined0 undefined2.36 undefined
2028e7.35 undefined0 undefined1.88 undefined
2027e6.04 undefined0 undefined1.37 undefined
2026e6.01 undefined0 undefined1.33 undefined
2025e5.55 undefined0 undefined1.16 undefined
2024e5.52 undefined0 undefined0.54 undefined
20233.57 undefined1.31 undefined2.07 undefined
20223.48 undefined2.17 undefined2.25 undefined
20214.16 undefined3.98 undefined2.82 undefined
20202.96 undefined2.83 undefined1.98 undefined
20192.3 undefined2.17 undefined1.39 undefined
20182.3 undefined2.1 undefined3.48 undefined
20171.81 undefined1.53 undefined1.12 undefined
20161.08 undefined0.88 undefined0.48 undefined
20150.47 undefined0.27 undefined-0.16 undefined
20140.07 undefined-0.3 undefined-1.5 undefined
20130.04 undefined-0.28 undefined-1.67 undefined
20121.49 undefined-0.14 undefined-0.2 undefined
20110.3 undefined-1.34 undefined-1.4 undefined
20100.34 undefined-1.09 undefined-1.16 undefined
20090.39 undefined-1.27 undefined-1.35 undefined
20080.38 undefined-1.43 undefined-1.52 undefined
20070.36 undefined-2.79 undefined-2.64 undefined
20060.33 undefined-3.04 undefined-2.81 undefined
20050.23 undefined-2.81 undefined-2.69 undefined
20040.27 undefined-3.2 undefined-3.08 undefined

Innoviva business model

Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva is one of the most popular companies on Eulerpool.com.

Innoviva SWOT Analysis

Strengths

Innoviva Inc has a strong portfolio of patented respiratory products, providing a competitive advantage in the market. This allows the company to maintain a significant market share and generate substantial revenue.

The company has a highly experienced and skilled research and development team, constantly exploring innovative solutions to address respiratory diseases. This expertise enables Innoviva to stay ahead of its competitors and develop cutting-edge products.

Weaknesses

Innoviva heavily relies on partnerships for the commercialization of its products, which can result in limited control over pricing and distribution. This dependence on partners may impact the company's profitability.

The company's product pipeline is relatively limited, with a focus on respiratory medications. This narrow focus may limit Innoviva's ability to explore other profitable therapeutic areas.

Opportunities

The global respiratory therapeutic market is expected to grow significantly in the coming years, presenting a tremendous opportunity for Innoviva to expand its market share and generate increased revenue.

Innoviva can explore strategic partnerships or acquisitions to diversify its product offerings and enter new therapeutic areas. This would allow the company to tap into additional revenue streams and enhance its competitive position.

Threats

Intense competition in the respiratory therapeutic market poses a threat to Innoviva's market share and pricing power. Competitors may introduce alternative products or pricing strategies that could result in reduced profitability.

The regulatory environment surrounding respiratory medications is subject to changes and uncertainties. Changes in regulations or the introduction of new requirements may impact Innoviva's ability to bring products to market and generate revenue.

Innoviva Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Innoviva historical P/E ratio, EBIT, and P/S ratio.

Innoviva shares outstanding

The number of shares was Innoviva in 2023 — This indicates how many shares 86.876 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Innoviva earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Innoviva's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Innoviva’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Innoviva's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Innoviva dividend history and estimates

In 2023, Innoviva paid a dividend amounting to 0 USD. Dividend means that Innoviva distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Innoviva provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Innoviva’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Innoviva's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Innoviva Dividend History

DateInnoviva Dividend
20150.75 undefined
20140.5 undefined

Innoviva dividend payout ratio

In 2023, Innoviva had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Innoviva distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Innoviva represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Innoviva could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Innoviva's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Innoviva Payout Ratio History

DateInnoviva Payout ratio
2029e0 %
2028e0 %
2027e0 %
2026e0 %
2025e0 %
2024e0 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
2015-468.75 %
2014-33.33 %
20130 %
20120 %
20110 %
20100 %
20090 %
20080 %
20070 %
20060 %
20050 %
20040 %
Unfortunately, there are currently no price targets and forecasts available for Innoviva.

Innoviva latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.24 -0.55  (-329.45 %)2024 Q2
3/31/20240.17 0.46  (165.28 %)2024 Q1
12/31/20230.23 0.76  (223.96 %)2023 Q4
9/30/20230.28 0.98  (255.85 %)2023 Q3
6/30/20230.27 0.02  (-92.46 %)2023 Q2
3/31/20230.23 0.42  (79.03 %)2023 Q1
12/31/20220.23 -0.98  (-527.02 %)2022 Q4
9/30/20222.29 2.8  (22.37 %)2022 Q3
6/30/20221.96 0.05  (-97.45 %)2022 Q2
3/31/20220.45 0.35  (-22.01 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Innoviva stock

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

60

👫 Social

49

🏛️ Governance

54

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Innoviva list of shareholders

%
Name
Stocks
Change
Date
7.22 % Dimensional Fund Advisors, L.P.4,516,99966,29512/31/2023
6.62 % Renaissance Technologies LLC4,144,447145,04012/31/2023
4.18 % Westfield Capital Management Company, L.P.2,614,127569,11712/31/2023
4.03 % State Street Global Advisors (US)2,518,778150,46512/31/2023
3.46 % Systematic Financial Management, L.P.2,165,911-36,75612/31/2023
2.76 % Pacer Advisors, Inc.1,728,9841,727,53412/31/2023
2.60 % Morgan Stanley & Co. LLC1,627,4791,274,50112/31/2023
2.10 % Geode Capital Management, L.L.C.1,311,27238,37512/31/2023
14.82 % BlackRock Institutional Trust Company, N.A.9,270,201698,53912/31/2023
11.63 % Sarissa Capital Management, L.P.7,277,000012/31/2023
1
2
3
4
5
...
10

Innoviva Executives and Management Board

Mr. Pavel Raifeld40
Innoviva Chief Executive Officer
Compensation 1.8 M
Ms. Marianne Zhen54
Innoviva Chief Accounting Officer
Compensation 771,131
Mr. Jules Haimovitz72
Innoviva Independent Director
Compensation 523,541
Dr. Sarah Schlesinger63
Innoviva Independent Director
Compensation 435,121
Dr. Odysseas Kostas48
Innoviva Director
Compensation 407,490
1
2

Most common questions regarding Innoviva

What values and corporate philosophy does Innoviva represent?

Innoviva Inc is committed to delivering value to its shareholders and stakeholders through innovation and collaboration. The company's corporate philosophy is focused on providing innovative solutions in the field of respiratory diseases. Innoviva Inc prides itself on fostering a culture of excellence, integrity, and patient-centricity. With a dedicated team and strategic partnerships, the company strives to enhance the quality of life for individuals suffering from respiratory conditions. Innoviva Inc's commitment to research, development, and commercialization of novel therapies underscores its mission to make a meaningful difference in the lives of patients worldwide.

In which countries and regions is Innoviva primarily present?

Innoviva Inc is primarily present in the United States.

What significant milestones has the company Innoviva achieved?

Innoviva Inc, a leading stock company, has achieved several significant milestones throughout its history. The company has successfully forged strategic partnerships with renowned pharmaceutical companies, facilitating the development and commercialization of innovative respiratory therapies. Innoviva Inc has also consistently delivered impressive financial results, showcasing its strong market position and value creation for shareholders. Furthermore, the company has been focused on enhancing its pipeline of respiratory products and expanding its global footprint. With its continued commitment to innovation and strategic growth, Innoviva Inc remains a prominent player in the stock market, presenting lucrative opportunities for investors.

What is the history and background of the company Innoviva?

Innoviva Inc, formerly known as Theravance Inc, is a biopharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 1996, Innoviva has a rich history of partnering with leading pharmaceutical companies to bring breakthrough treatments to market. With a focus on respiratory diseases, Innoviva is committed to improving the lives of patients suffering from conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company has an impressive portfolio of products and continues to invest in research and development to address unmet medical needs. Innoviva's dedication to innovation and strategic collaborations has positioned it as a leader in the biopharmaceutical industry.

Who are the main competitors of Innoviva in the market?

The main competitors of Innoviva Inc in the market include pharmaceutical and biotechnology companies such as GlaxoSmithKline, Novartis, AstraZeneca, and Merck & Co.

In which industries is Innoviva primarily active?

Innoviva Inc is primarily active in the healthcare and pharmaceutical industries.

What is the business model of Innoviva?

Innoviva Inc's business model focuses on the development and commercialization of new therapies for respiratory diseases. The company collaborates with pharmaceutical partners to license and acquire royalty interests in their products. By monetizing these interests, Innoviva generates a steady stream of revenue, allowing them to invest in research and development activities. This strategic approach ensures a diversified portfolio of respiratory medicines and enables Innoviva to support the innovation and advancement of healthcare solutions.

What is the P/E ratio of Innoviva 2024?

The Innoviva P/E ratio is 48.99.

What is the P/S ratio of Innoviva 2024?

The Innoviva P/S ratio is 4.8.

What is the AlleAktien quality score of Innoviva?

The AlleAktien quality score for Innoviva is 4/10.

What is the revenue of Innoviva 2024?

The expected Innoviva revenue is 345.38 M USD.

How high is the profit of Innoviva 2024?

The expected Innoviva profit is 33.82 M USD.

What is the business model of Innoviva

Innoviva Inc. is a publicly traded company based in California, USA, that focuses on the development and marketing of medications in collaboration with its partners. The company has two main business areas: partnerships with the pharmaceutical industry and the sale of licenses. In the first area, Innoviva specializes in the development of medications for respiratory diseases and has partnerships with leading pharmaceutical companies such as GlaxoSmithKline and Theravance Biopharma. In the second area, Innoviva offers its extensive patent portfolio to partner companies for use and actively seeks potential partners who can benefit from certain patents. Overall, Innoviva has a strong position in the respiratory disease market and is known for its innovative and effective medications.

What is the Innoviva dividend?

Innoviva pays a dividend of 0 USD distributed over payouts per year.

How often does Innoviva pay dividends?

The dividend cannot currently be calculated for Innoviva or the company does not pay out a dividend.

What is the Innoviva ISIN?

The ISIN of Innoviva is US45781M1018.

What is the Innoviva WKN?

The WKN of Innoviva is A2AC9U.

What is the Innoviva ticker?

The ticker of Innoviva is INVA.

How much dividend does Innoviva pay?

Over the past 12 months, Innoviva paid a dividend of 0.75 USD . This corresponds to a dividend yield of about 3.93 %. For the coming 12 months, Innoviva is expected to pay a dividend of 0 USD.

What is the dividend yield of Innoviva?

The current dividend yield of Innoviva is 3.93 %.

When does Innoviva pay dividends?

Innoviva pays a quarterly dividend. This is distributed in the months of December, April, July, October.

How secure is the dividend of Innoviva?

Innoviva paid dividends every year for the past 0 years.

What is the dividend of Innoviva?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innoviva located?

Innoviva is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innoviva kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innoviva from 9/30/2015 amounting to 0.25 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2015.

When did Innoviva pay the last dividend?

The last dividend was paid out on 9/30/2015.

What was the dividend of Innoviva in the year 2023?

In the year 2023, Innoviva distributed 0 USD as dividends.

In which currency does Innoviva pay out the dividend?

The dividends of Innoviva are distributed in USD.

All fundamentals about Innoviva

Our stock analysis for Innoviva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innoviva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.